Nilo Therapeutics launched with $101 million in Series A funding to translate neuro‑immunology discoveries into drugs that target neural circuits to control systemic inflammation. The company was founded by academics from Columbia, Yale and Harvard and will advance programs based on vagal and other brain‑immune master regulators identified in basic neuroscience labs. The financing was led by The Column Group, DCVC Bio and Lux Capital with contributions from Gates Foundation and Alexandria. Nilo will establish labs in New York, expand R&D headcount, and progress preclinical candidates aimed at autoimmune and inflammatory diseases. Clarification: the company’s approach aims to modulate neural circuits that drive peripheral immune responses rather than directly targeting immune cells.